已收盘 11-20 16:00:00 美东时间
-0.310
-9.06%
Immutep posts an 81.1% 12-month disease-free survival rate in its Phase 2 soft tissue sarcoma study and plans a new trial in 2027.
11-19 20:44
Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
11-12 00:27
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash
09-30 20:06
Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and mixed analyst views weigh on outlook.
04-16 00:40
US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services down 1.2%. PCE index rose 2.8%, GDP up 0.7%.
03-14 01:01
Citizens analyst Reni Benjamin downgrades Immutep (NASDAQ:IMMP) from Market Outperform to Market Perform.
03-13 18:34
Immutep shares update on Phase I study of LAG-3 agonist antibody for autoimmune diseases, showing positive safety & efficacy data.
2025-12-23 01:59
Immutep's IMP761 shows significant T-cell suppression and favorable safety at 0.9 mg/kg in Phase I, targeting autoimmune diseases. Higher doses (2.5, 7, 14 mg/kg) are planned, with more data expected in H2 2025.
2025-06-23 12:00
Immutep Limited's clinical trial combining eftilagimod alfa (efti) with radiotherapy and pembrolizumab has met its primary endpoint in resectable soft tissue sarcoma, achieving significant tumor hyalinization/fibrosis beyond the prespecified median and historical data, indicating improved outcomes for patients. Detailed results are planned for future presentation.
2025-05-27 12:00
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0%
2024-09-16 20:15